NIO-1, a novel inhibitor of OCT1, enhances the antitumor action of radiofrequency ablation against hepatocellular carcinoma.
Current molecular medicine(2023)
摘要
This study demonstrated the clinical importance of OCT1 expression in HCC for the first time. Our findings also revealed that NIO-1 aids RFA therapy by targeting OCT1.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要